Corrigendum: Evaluation of herb–drug interaction between Danshen and rivaroxaban in rat and human liver microsomes(Front. Pharmacol., (2022), 13, (950525), 10.3389/fphar.2022.950525)

  • Xu Wang
  • , Jingjing Fa
  • , Yuanjin Zhang
  • , Shengbo Huang
  • , Jie Liu
  • , Junqing Gao
  • , Lina Xing
  • , Zongjun Liu*
  • , Xin Wang*
  • *Corresponding author for this work

Research output: Contribution to journalComment/debate

1 Scopus citations

Abstract

In the published article, there was an error in affiliation 1. Instead of “Department of Cardiology, Central Hospital of Shanghai Putuo District, Shanghai University of Traditional Chinese Medicine, Shanghai, China”, it should be “Department of Cardiology, Putuo Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China”. The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Original languageEnglish
Article number1039267
JournalFrontiers in Pharmacology
Volume13
DOIs
StatePublished - 5 Oct 2022

Keywords

  • Danshen
  • cytochrome P 450 (CYP)
  • herb-drug interaction
  • metabolism
  • rivaroxaban

Fingerprint

Dive into the research topics of 'Corrigendum: Evaluation of herb–drug interaction between Danshen and rivaroxaban in rat and human liver microsomes(Front. Pharmacol., (2022), 13, (950525), 10.3389/fphar.2022.950525)'. Together they form a unique fingerprint.

Cite this